- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07951489
At Home Use of Noninvasive Vagus Nerve Stimulation Following TBI to Improve Cognition.
Randomized, Sham-controlled Clinical Trial Testing At-home Use of Noninvasive Vagus Nerve Stimulation After TBI
The purpose of this study is to evaluate whether individuals with TBI can comfortably and consistently use transcutaneous vagus nerve stimulation (tVNS) at home and to identify barriers that may affect participation. A secondary objective is to obtain preliminary data to examine whether at-home tVNS is associated with improvement in cognitive skills as well as any improvement in patient reported outcomes such as sleep, mood, or fatigue.
Study Overview
Status
Conditions
Detailed Description
This is a sham controlled pilot study to evaluate the feasibility and preliminary efficacy of remotely supervised, at-home delivery of tVNS in individuals with TBI during the post-acute recovery phase. Eligible participants will complete a 4-week tVNS intervention protocol at home. Mixed methods (quantitative and qualitative) will be used to evaluate outcomes. Eligible participants will be invited to initial baseline assessment and tVNS training session (Visit 1). Then, they will be randomly allocated to recieve either active or sham stimulation for the first two weeks of at-home administration period. They will then return for a min-intervention assessment (Visit 2). After the mid-intervention assessment, they will return home and recieve active stimulation for the remaining two weeks. Lastly, they will return to a post- intervention assessment (Visit 3). In the assessment sessions participants will complete tasks of set shifting and working memory, core executive functions, as well as complete surveys regarding fatigue, sleep, and overall quality of life.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kathryn Magee, MHS., CCC-SLP/L, CBIS
- Phone Number: 312 238 6451
- Email: tvns_research@sralab.org
Study Contact Backup
- Name: Shira Cohen-Zimerman, PhD
- Phone Number: 312 238 6450
- Email: tvns_research@sralab.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Shirley Ryan AbilityLab
-
Chicago, Illinois, United States, 60611
- Not yet recruiting
- Shirley Ryan AbilityLab
-
Principal Investigator:
- Elliot Roth, MD
-
Contact:
- Kathryn Magee, MHS., CCC-SLP/L, CBIS
- Phone Number: 312 238 6451
- Email: tvns_research@sralab.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75 years Formally diagnosed with traumatic brain injury.
- Ability to independently use a keyboard.
- Ability to independently apply the electrode and adjust stimulation or have a designated caregiver available to be trained and assist with these tasks.
- Able to understand and communicate in English (according to clinical judgment).
- Able to independently provide consent to participate. -Able to come in person to Shirley Ryan AbilityLab in Chicago, IL for three visits over 5 weeks.
Exclusion Criteria:
- Acute medical issues requiring close physician or nursing monitoring. Bioelectrical implants, cerebral shunts, including pacemakers.
- Anyone with sore or diseased skin area in the ear
- Pregnancy or persons who are lactating.
- Cardiac arrhythmia.
- Epilepsy or seizure disorders.
- Significant gross or fine motor weakness.
- Significant, ongoing communication or comprehension impairments (such as aphasia) that would affect an individual's ability to complete the required assessments.
- Severely impaired memory retention
- Current major depression diagnosis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active Stimulation
Initial baseline assessment completed Day 0. Active stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device , for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, another two weeks (Day 16-29) of active stimulation at home followed by a post intervention assessment session. |
tVNS stimulation at home for atleast one hour a day for 4 weeks. |
|
Sham Comparator: Sham Stimulation
Initial baseline assessment completed Day 0. Sham stimulation using Tancutaneous Vagus Nerve Stimulation (tVNS) device, for atleast one hour a day for 14 days at home (Day1-14). A mid intervention assessment session completed on Day 15. Following that assessment, participant will switch to recieve active stimulation for the remaining 2 week at home (Day 16-29) followed by a post intervention assessment session. |
Participants will recieve two weeks of sham stimulation for atleast one hour a day, followed by 2 weeks of active stimulation for atleast one hour a day. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Recording the number of participant who completed at least 75% of the sessions out of the number of participants enrolled in the study.
Time Frame: Post Intervention Assessment Day 30
|
Post Intervention Assessment Day 30
|
|
Semi-structured interviews will collect feedback on perceived benefit, usability, logistical challenges, and barriers to adherence.
Time Frame: Post Intervention Assessment Session Day 30
|
Post Intervention Assessment Session Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
N-Back
Time Frame: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
In the N-Back Task, participants are presented a series of visual stimuli. They are asking for each stimulus whether is matches a stimulus n-trials before. For example, in a 2-back task, in which the trials consist of letters, participants have to decide whether the current letter is the same as the letter in the trial n-2. We will use a computerized version of this task. |
Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
|
California Verbal Learning Test
Time Frame: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
The California Verbal Learning Test evaluates the ability to encode, recall, and recognize verbally presented information across multiple learning trials and delayed recall conditions. Participants are read multiple lists of words and asked to recall specific words at different time allotments. |
Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
|
Trail Making A&B
Time Frame: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
Trail Making Part A requires participant to draw a line between circles containing numbers in ascending order. Part B requires participants to alternate drawing a line between ascending letters and numbers. The key measures are the time required to complete and the number of errors made in Part A and Part B. The test measures various aspects of cognition including attention, visual search, motor coordination, reasoning, and task switching. |
Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
|
Conners Continuous Performance Test 3rd Edition
Time Frame: Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
CPT-3 is a computerized task requires of pressing the space bar on a computer keyboard after any letter is presented on the screen, except for the letter "X". This test lasts about 14 minutes. It measures several aspects of sustained attention, including inattention, impulsivity, and vigilance captured by measuring response styles, errors, and response times. |
Baseline Assessment: Day 0, Mid Intervention Assessment: Day 15, Post Intervention Assessment: Day 30
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00226736
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.